Publications by authors named "John Woolcott"

Claim this Profile
E
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program.
Bruce E Sands, Marla C Dubinsky, Paulo G Kotze, Séverine Vermeire, Remo Panaccione, John C Woolcott

Inflamm Bowel Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.
Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, Peter M Irving, Rupa Banerjee, John C Woolcott

Inflamm Bowel Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme.
María Chaparro, Remo Panaccione, Bruce E Sands, Peter M Irving, Martina Goetsch, John C Woolcott

BMJ Open Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial.
Evan S Dellon, Margaret H Collins, Albert J Bredenoord, Hamish Philpott, Luc Biedermann, John C Woolcott

Lancet Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
Vipul Jairath, David T Rubin, Bram Verstockt, Ayhan H Çekin, Maria T Abreu, John C Woolcott

Inflamm Bowel Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program.
Bruce E Sands, Yvette Leung, David T Rubin, Krisztina B Gecse, Julian Panés, John C Woolcott

J Crohns Colitis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, Geert R D'Haens, Julian Panés, John C Woolcott

J Crohns Colitis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts.
David T Rubin, Joana Torres, Iris Dotan, Lan Terry Xu, Irene Modesto, John C Woolcott

Inflamm Bowel Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Christina Charles-Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R Ytterberg, John C Woolcott

Arthritis Rheumatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib.
Sara van Gennep, Ivan C N Fung, Djuna C de Jong, Rishand K Ramkisoen, Esmé Clasquin, John C Woolcott

J Crohns Colitis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presence of risk factors associated with colectomy among patients with ulcerative colitis: a analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program.
David T Rubin, Leonardo Salese, Mitchell Cohen, Paulo G Kotze, John C Woolcott

Therap Adv Gastroenterol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
Marla C Dubinsky, Alessandro Armuzzi, Krisztina B Gecse, Thomas Ullman, Andrew G Bushmakin, John C Woolcott

Dig Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program.
Edward V Loftus, Daniel C Baumgart, Krisztina Gecse, Jami A Kinnucan, Susan B Connelly, John C Woolcott

Inflamm Bowel Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
Kevin L Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, John C Woolcott

Rheumatol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
David P Hudesman, Joana Torres, Leonardo Salese, John C Woolcott, Rajiv Mundayat

Patient· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
Boulos Haraoui, Majed Khraishi, Denis Choquette, Larissa Lisnevskaia, Michelle Teo, John C Woolcott

Arthritis Care Res (Hoboken)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis.
Kurt de Vlam, Philip J Mease, Andrew G Bushmakin, Roy Fleischmann, Alexis Ogdie, John Woolcott

Rheumatol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.
William J Sandborn, Alessandro Armuzzi, Giuseppina Liguori, Peter M Irving, Ala I Sharara, John C Woolcott

Inflamm Bowel Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate Combination.
Stanley B Cohen, Boulos Haraoui, Jeffrey R Curtis, Timothy W Smith, John Woolcott

Clin Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open.
Remo Panaccione, Maria T Abreu, Irina Lazariciu, Rajiv Mundayat, Nervin Lawendy, John C Woolcott

Aliment Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.
Ara Dikranian, David Gold, Louis Bessette, Peter Nash, Valderilio F Azevedo, John Woolcott

Rheumatol Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months.
Vivian P Bykerk, Eun Bong Lee, Ronald van Vollenhoven, David C Gruben, Lara Fallon, John C Woolcott

Arthritis Care Res (Hoboken)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients' and Physicians' View.
Marla C Dubinsky, Kenji Watanabe, Pauliina Molander, Laurent Peyrin-Biroulet, Michele Rubin, John Woolcott

Inflamm Bowel Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib.
Kurt de Vlam, Alexis Ogdie, Andrew G Bushmakin, Joseph C Cappelleri, Roy Fleischmann, John Woolcott

RMD Open· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry.
Manasi Agrawal, Erica J Brenner, Xian Zhang, Irene Modesto, John Woolcott

Inflamm Bowel Dis· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis